The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Lorenzo Falchi
No relevant relationships to disclose
Michael J. Keating
Consultant or Advisory Role - Celgene; GlaxoSmithKline
Honoraria - Celgene; GlaxoSmithKline
Xavier C. Badoux
No relevant relationships to disclose
William G. Wierda
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene; GlaxoSmithKline
Susan Mary O'Brien
Consultant or Advisory Role - Celgene; GlaxoSmithKline
Susan C. Smith
No relevant relationships to disclose
Sijin Wen
No relevant relationships to disclose
Hagop Kantarjian
No relevant relationships to disclose
Alessandra Ferrajoli
Research Funding - Celgene; GlaxoSmithKline